Inventia Healthcare Limited initiated a voluntary blood pressure medication recall on June 5, pulling 11,460 bottles of Chlorthalidone Tablets USP, 25 mg from the U.S. market after the tablets failed dissolution specifications. The recall covers both 100-count and 1,000-count bottles distributed nationwide by Rising Pharma Holdings Inc. of New Jersey.
That matters because chlorthalidone is commonly prescribed to treat high blood pressure and fluid retention, and a tablet that does not dissolve properly may not deliver medicine as intended in the body. For patients, that is the central risk: a familiar medicine can look unchanged on the shelf while behaving differently once swallowed.
The recall was initiated after a manufacturing issue was discovered, but the exact problem has not been publicly detailed. No public press release has been issued, and the Food and Drug Administration has not yet assigned a classification to the recall, leaving the scope of urgency defined for now by the 11,460-bottle total rather than by a formal enforcement label.
The unanswered question is narrower and more practical: which specific lots and expiration dates are included. Until that is spelled out, the recall remains a nationwide warning tied to a widely used medicine, with the next official step still pending from the FDA.
